磺达肝癸钠结构式
|
常用名 | 磺达肝癸钠 | 英文名 | Fondaparinux Sodium |
---|---|---|---|---|
CAS号 | 114870-03-0 | 分子量 | 1738.16 | |
密度 | N/A | 沸点 | N/A | |
分子式 | C31H53N3Na10O49S8 | 熔点 | N/A | |
MSDS | 美版 | 闪点 | N/A |
磺达肝癸钠用途Fondaparinux sodium 是一种抗凝血酶依赖性的 factor Xa 抑制剂。 |
中文名 | 磺达肝癸钠 |
---|---|
英文名 | fondaparinux sodium |
中文别名 | 磺达肝素(癸)钠 | 磺达肝素钠 |
英文别名 | 更多 |
描述 | Fondaparinux sodium 是一种抗凝血酶依赖性的 factor Xa 抑制剂。 |
---|---|
相关类别 | |
靶点 |
Factor Xa[1] |
体外研究 | 磺达肝素钠是第一种选择性靶向Xa因子的新型抗凝血剂。对于磺达肝素,其活化单核细胞(ac-M)的IC50值(抗-Xa IU/ml)为0.59±0.05,单核细胞衍生的微粒(MMP)为0.17±0.03 [2]。 |
体内研究 | 磺达肝素钠具有线性,剂量依赖性药代动力学特征,其提供高度可预测的响应。磺达肝素钠具有100%生物利用度,起效迅速,半衰期为14至16小时,可在24小时内持续抗血栓形成。该药物不影响凝血酶原时间或活化部分促凝血酶原激酶时间,也不影响血小板功能或聚集[1]。 |
参考文献 |
分子式 | C31H53N3Na10O49S8 |
---|---|
分子量 | 1738.16 |
PSA | 900.82000 |
储存条件 | -20°C,惰性气体存储 |
危险品运输编码 | NONH for all modes of transport |
---|
Structural Evidence for the Tetrameric Assembly of Chemokine CCL11 and the Glycosaminoglycan Arixtra™.
Biomolecules 3 , 905-22, (2014) Understanding chemokine interactions with glycosaminoglycans (GAG) is critical as these interactions have been linked to a number of inflammatory medical conditions, such as arthritis and asthma. To b... |
|
Bioengineered heparins and heparan sulfates.
Adv. Drug Deliv. Rev. 97 , 237-49, (2016) Heparin and heparan sulfates are closely related linear anionic polysaccharides, called glycosaminoglycans, which exhibit a number of important biological and pharmacological activities. These polysac... |
α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), decasodium salt |
Decasodium methyl 2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-β-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-2- O-sulfonato-α-L-idopyranuronosyl-(1->;4)-2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranoside |
α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10) |
Fondaparin sodium |
Arixtra |
Fondaparinux sodium |
α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4 )-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10) |
Fondaparinux (sodium) |